The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia

getITD for FLT3-ITD-based MRD monitoring in AML

(2019) Tamara J. Blätte et al.   LEUKEMIA

Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia

(2019) Christine M. McMahon et al.   Cancer Discovery

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

(2019) Alexander E. Perl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Time to repeal and replace response criteria for acute myeloid leukemia?

(2018) Clara Derber Bloomfield et al.   BLOOD REVIEWS

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

(2018) Jorge Cortes et al.   LANCET ONCOLOGY

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

(2018) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of FLT3-ITD length on prognosis of acute myeloid leukemia

(2018) Song-Bai Liu et al.   HAEMATOLOGICA

The emerging role of measurable residual disease detection in AML in morphologic remission

(2018) F. Buccisano et al.   SEMINARS IN HEMATOLOGY

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

(2018) Eytan M. Stein et al.   BLOOD

Minimal residual disease in acute myelogenous leukemia

(2017) N. M. Cruz et al.   International Journal of Laboratory Hematology

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

(2017) Masamichi Mori et al.   INVESTIGATIONAL NEW DRUGS

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

(2017) Alexander E Perl et al.   LANCET ONCOLOGY

Methods of Detection of Measurable Residual Disease in AML

(2017) Yi Zhou et al.   Current Hematologic Malignancy Reports

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

(2016) Lauren Y. Lee et al.   BLOOD

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

(2015) D. F. Angelini et al.   CLINICAL CANCER RESEARCH

Identification of emergingFLT3ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin

(2013) Tiziana Ottone et al.   BRITISH JOURNAL OF HAEMATOLOGY

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease

(2013) A Kohlmann et al.   LEUKEMIA

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

(2012) A. Sexauer et al.   BLOOD

Molecular analysis of differentFLT3-ITD mutations in acute myeloid leukemia

(2012) Olga Blau et al.   LEUKEMIA & LYMPHOMA

Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia

(2008) C. J. Hess et al.   HAEMATOLOGICA